0000000001183400

AUTHOR

Angela Märten

showing 1 related works from this author

Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung…

2015

8073 Background: Afatinib 40 mg/day (oral) is approved for the treatment of pts with advanced EGFRm+ NSCLC. Dose adjustment is recommended according to pre-defined tolerability criteria. We perform...

Pulmonary and Respiratory MedicineBrachial Plexus NeuritisOncologyCancer Researchmedicine.medical_specialtybusiness.industryAfatinibMedizinnon-small cell lung cancer (NSCLC)HematologyPharmacologymedicine.diseasestomatognathic diseasesTolerabilityOncologyEgfr mutationDose adjustmentInternal medicinemedicineIn patientbusinessmedicine.drug
researchProduct